SCHEMBL917005

SCHEMBL917005

O=C1CCCCN1CCc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.68
SMN1; SMN2 Q16637 2/20 0.59
GAA P10253 2/20 0.59
ACHE P22303 1/20 0.59
MCHR1 Q99705 1/20 0.58
RAB9A P51151 3/20 0.56
NPC1 O15118 2/20 0.55
SLC6A3 Q01959 1/20 0.55
SIGMAR1 Q99720 1/20 0.53
KDM4E B2RXH2 1/20 0.50
MAPT P10636 2/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
USP2 O75604 1/20 0.49
HTT P42858 1/20 0.49
HSD17B10 Q99714 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5872163 0.98 L3MBTL1 (0.71) L3MBTL1SMN1; SMN2GAAACHEMCHR1
SCHEMBL2132367 0.95 L3MBTL1 (0.60) L3MBTL1SMN1; SMN2GAAACHEMCHR1
SCHEMBL5872083 0.89 L3MBTL1 (0.67) L3MBTL1SMN1; SMN2GAAACHEMCHR1
SCHEMBL11513541 0.87 NPC1 (0.58) L3MBTL1GAAACHEMCHR1RAB9A
SCHEMBL8882276 0.85 L3MBTL1 (0.57) L3MBTL1SMN1; SMN2GAAACHERAB9A
SCHEMBL4093054 0.85 MCHR1 (0.51) L3MBTL1SMN1; SMN2GAAACHEMCHR1
SCHEMBL8899205 0.83 HRH3 (0.57) L3MBTL1SMN1; SMN2GAAACHEMCHR1
SCHEMBL11323025 0.83 L3MBTL1 (0.51) L3MBTL1SMN1; SMN2GAAACHEMCHR1
2-Pyrrolidone SCHEMBL11038232 0.82 L3MBTL1 (0.48) L3MBTL1SMN1; SMN2GAAACHEMCHR1
SCHEMBL596252 0.82 L3MBTL1 (0.96) L3MBTL1SMN1; SMN2GAAACHERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250206884-A1 ULTRAVIOLET RADIATION-CURABLE POLYSILOXANE COMPOSITION, AND DAMPING MATERIAL TAICA CORPORATION (JP) 2025-06-26 US disclosed
CN-114763335-B 4-Amide piperidine derivative and preparation method and application thereof 江苏谛奇医药科技有限公司 2025-03-18 CN disclosed
WO-2023189433-A1 ULTRAVIOLET RADIATION-CURABLE POLYSILOXANE COMPOSITION, AND DAMPING MATERIAL 株式会社タイカ 2023-10-05 WO disclosed
CN-110456087-B Sertraline detection reagent and preparation and use methods thereof 苏州博源医疗科技有限公司 2022-09-20 CN disclosed
CN-114763335-A 4-amide piperidine derivative and preparation method and application thereof 江苏谛奇医药科技有限公司 2022-07-19 CN disclosed
CN-114751834-A Venlafaxine derivative, immunogen, anti-venlafaxine specific antibody, and preparation method and application thereof 长沙博源医疗科技有限公司 2022-07-15 CN disclosed
CN-114685400-A Aripiprazole key group derivative, immunogen, anti-aripiprazole specific antibody, and preparation method and application thereof 苏州博源医疗科技有限公司 2022-07-01 CN disclosed
CN-114685477-A Linezolid derivative, immunogen, anti-linezolid specific antibody, and preparation method and application thereof 苏州博源医疗科技有限公司 2022-07-01 CN disclosed
CN-114685342-A Levetiracetam derivative, immunogen, anti-levetiracetam specific antibody, preparation method and application thereof 长沙博源医疗科技有限公司 2022-07-01 CN disclosed
CN-114685527-A Olanzapine derivative, immunogen, anti-olanzapine specific antibody, preparation method and application thereof 苏州博源医疗科技有限公司 2022-07-01 CN disclosed
US-20080132540-A1 NON-PEPTIDIC NPY Y2 RECEPTOR INHIBITORS CARRUTHERS NICHOLAS I 2008-06-05 US disclosed
US-7317025-B2 Non-peptidic NPY Y2 receptor inhibitors JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, LLC (US) 2008-01-08 US disclosed
CN-1699349-A Method and reagents for N-alkylating ureides TARO PHARMA IND (IL) 2005-11-23 CN disclosed
WO-2005030754-A1 INDOLE OR QUINOLINE DERIVATIVES AS NON-PEPTICID NPY Y2 RECEPTOR INHIBITORS USEFUL FOR THE TREATMENT OF ANXIOLYTIC AND DEPRESSIVE DISORDERS AND OBESITY JANSSEN PHARMACEUTICA, N.V. (BE) 2005-04-07 WO disclosed
US-20050070534-A1 Non-peptidic NPY Y2 receptor inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-31 US disclosed
CN-1273581-A Process and reagent for N-alkylation of ureides TARO PHARMA IND (IL) 2000-11-15 CN disclosed
WO-1999032488-A1 METHOD FOR PREPARING A HYDANTOIN DERIVATIVE SUBSTITUTED IN POSITION 5, METHOD FOR PREPARING AN α-AMINO ACID ALKALINE SALT FROM SAID HYDANTOIN DERIVATIVE AND METHOD FOR ESTERIFYING CYCLIC α-AMINO ACIDS SERANALIS (FR) 1999-07-01 WO disclosed
US-4900738-A OPIOID ANTAGONISTS; REDUCE SIDE EFFECTS BOC, INC. (US) 1990-02-13 US disclosed
US-4791112-A ANALGESICS, NAQRCOTIC ANTAGONISTS THE BOC GROUP, INC. (US) 1988-12-13 US disclosed
US-4481360-A 4H-1,2,4-Triazol-3-yl compounds THE UPJOHN COMPANY (US) 1984-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132540-A1 NON-PEPTIDIC NPY Y2 RECEPTOR INHIBITORS NPY2R, NPY1R, NPY5R L3MBTL1 1163/4885SMN1; SMN2 1933/4885GAA 3862/4885
US-20050070534-A1 Non-peptidic NPY Y2 receptor inhibitors NPY2R, NPY1R, NPY5R L3MBTL1 1163/4885SMN1; SMN2 1933/4885GAA 3862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.